CLINICAL_TRIALS
trial_result
· 2017-10-18
Clinical Trial Update: A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis [Phase 1]
Summary
A completed Phase 1 safety study assessing carfilzomib in patients with previously treated systemic light-chain amyloidosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Criterium, Inc. | Conditions: Amyloidosis, Systemic Light Chain Amyloidosis | Phase 1 | Status: COMPLETED